HOME >> MEDICINE >> NEWS
Study Pinpoints Effectiveness Of Prostate Cancer Therapies To Patient Populations

Outcomes Measured In Relation To Radical Prostectomy, External Beam Radiation, And Seen Implant Therapy

Philadelphia, PA--Implanting radioactive-filled seeds into a cancerous prostate gland has been a largely sucessful method of treating the second-leading cancer killer among men for more than two decades. However, a new study says that, after an estimated 41-month follow-up, patients classified as high-risk had a poorer outcome after being treated with the seed implant therapy compared to those who underwent either radical prostectomy or external beam radiation. These findings are published in the September 16, 1998 issue of the Journal of the American Medical Association (JAMA). The study also concluded that no significant difference in outcome was noted in low risk patients across all treatment modalities for this short and limited follow-up period.

"These results suggest that a particular population of patients -- those we can pre-therapeutically determine to be "high risk" -- don't do as well with the seed therapy as judged by prostate specific antigen (PSA) levels, as with alternative forms of therapy," says Alan Wein, MD, senior investigator on the study and chief of urology at the University of Pennsylvania Cancer Center.

Penn researchers used collected data from 1,872 men who were treated for their localized prostate cancer between 1989 and 1997. The men underwent one of three treatment options: radical prostectomy, external beam radiation, or seed implant therapy offered at two clinical sites.

The researchers set out to measure the rate of disease-free survival for these patients. In doing so, they used three tests: PSA, biopsy Gleason score, and the American Joint Commission on Cancer staging (AJCC) T-stage.

As background, PSA blood tests measure the level of prstate-specific antigens in the blood: the results are reported as nanograms per milli
'"/>

Contact: Sue Montgomery
smontgom@mail.med.upenn.edu
(215) 349-5657
University of Pennsylvania School of Medicine
16-Sep-1998


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:11/22/2014)... 2014 Recently, UWDress.com, a successful wedding dress ... guest attire in order to prepare for the wedding ... to 70% off. , UWDress.com is a reliable company ... beautiful, especially the new items -- formal wedding guest attire. ... current market, including superstar and princess. As one of the ...
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... 2014 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) ... allegedly developed Type 2 diabetes due to its use ... now underway in U.S. District Court, District of South ... the litigation will convene its next Status Conference on ... Lead Counsel for Plaintiffs and Defendants to meet and ...
(Date:11/22/2014)... The Sports Conflict Institute is pleased to ... team of conflict resolution professionals. Baroff comes to SCI as ... has over 30 years experience as an arbitrator, educator, and ... to connect with SCI and bring my conflict resolution skills ... with a complete sports focus,” says Baroff. , “Roy has ...
Breaking Medicine News(10 mins):Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3
(Date:11/21/2014)... WOODLANDS, Texas , Nov. 21, 2014  Lexicon ... the pricing of its previously announced underwritten public offering ... to an effective shelf registration statement. The offering will ... public offering price of $1.005 per share.  Lexicon has ... up to 7,462,687 additional shares of common stock.  All ...
(Date:11/18/2014)... 2014  NxStage ® Medical Inc. (Nasdaq: ... innovative dialysis products , today announced the ... for the in-center, hemodialysis market.  Streamline Express features ... to reduce the amount of labor required for ... touch point contamination sites.  The dialyzer enables achievement ...
(Date:11/18/2014)... 2014  Sanguine Biosciences – a biotechnology company ... recruitment – will use its proprietary mobile application ... Inc. find and recruit people diagnosed with Congenital ... to participate in voluntary research, which will be ... hopefully aid in informing the development of potential ...
Breaking Medicine Technology:Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2
Cached News: